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Cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) is endogenously
expressed in human but not rodent white adipocytes. We performed a bioinformatic analysis of
the human CIDEA sequence and found conserved amino-acid motifs involved in binding to nuclear
receptors. Protein–protein binding experiments and transactivation assays conﬁrmed that CIDEA
binds to liver X receptors and regulates their activity in vitro. Cell fractionation demonstrated that
CIDEA localizes to both the cytoplasm and the nucleus in human white adipocytes. The interaction
between CIDEA and nuclear receptors could therefore be of importance for the regulation of meta-
bolic processes in human adipose tissue.
Structured summary:
LXR-beta binds to CIDEA by pull down (View interaction)
TIF2 and LXR-beta physically interact by two hybrid (View interaction)
LXR-beta binds to RAP250 by pull down (View interaction)
CIDEA and LXR-beta physically interact by two hybrid (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction most up-regulated gene in human subcutaneous adipose tissueCell death-inducing DNA fragmentation factor alpha-like effec-
tor A (CIDEA) is a protein of 25 kDa that belongs evolutionarily to
a family of cell death activators [1]. Although its exact functions
are not clear, a number of recent reports have shown that CIDEA
is involved in the regulation of lipid metabolism and energy expen-
diture. Ablation of CIDEA in mice causes a lean phenotype with in-
creased energy expenditure and enhanced lipolysis [2]. In humans,
CIDEA is highly and almost exclusively expressed in white fat cells
[3,4]. Following diet-induced weight reduction, CIDEA was thechemical Societies. Published by E
gmentation factor alpha-like
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ncikiene).[5]. A polymorphism in the human CIDEA gene, resulting in an ami-
no acid substitution (V115F), is associated with protection against
obesity [6]. Furthermore, low CIDEA expression in human adipo-
cytes in vivo is associated with several features of the metabolic
syndrome, such as increased waist circumference, accelerated ba-
sal (spontaneous) lipolysis and insulin resistance [4,7]. In addition,
CIDEA knock-down in white human fat cells results in increased
lipolysis [4]. Finally, CIDEA expression is upregulated in the fat
cells of cancer cachexia patients and over-expression of CIDEA in
fat cells inhibits glucose and stimulates fatty acid oxidation [8].
These human data suggest that CIDEA is involved in the regulation
of fat mass in white fat cells.
However, the molecular mechanism of action of CIDEA and its
intracellular localization are not clear and there appears to be
important inter-cellular differences. Thus, in murine brown adipo-
cytes, the green ﬂuorescence protein (GFP)-mCIDEA fusion protein
has been reported to localize to mitochondria [2]. In contrast, a
hemagglutinin-tagged murine CIDEA was localized to the endo-lsevier B.V. All rights reserved.
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FLAG-tagged CIDEA stably over-expressed in MCF-7 cells shuttled
between the nucleus and the cytoplasm [10]. In white adipocytes,
an over-expressed CIDEA-fusion protein (CIDEA-GFP or CIDEA-V5)
localized to lipid droplets [7,11]. Admittedly, it is difﬁcult to con-
ceive how CIDEA localized to the lipid droplet could affect the
expression of enzymes involved in fatty acid metabolism [8].
The present study was undertaken to elucidate the intracellular
localization of CIDEA in human white adipocytes and its possible
interaction with other intracellular proteins.2. Materials and methods
2.1. Cell culture
Human subcutaneous mature fat cells were obtained and puri-
ﬁed from healthy subjects as described previously [12]. Isolated
mature fat cells were used to obtain large amounts of adipocyte
protein for immunoprecipitation studies. Isolation and differentia-
tion of human adipocyte precursor cells from the stroma-vascular
fraction was performed as described [13,14]. COS-7 cells and 3T3-
L1 adipocytes (a murine fat cell line) were cultured and differenti-
ated according to standard protocols.2.2. Adenovirus infection and detection of cytosolic and nuclear
proteins
Human CIDEA cDNA was cloned into pDUAL-CCM-EGFP adenovi-
ral vector (VectorBiolabs, Philadelphia, PA) and adenovirus particles
were produced by VectorBiolabs. Adenoviral infections were per-
formed in human in vitro differentiated adipocytes as previously de-
scribed [15]. The GFP-expressing adenovirus was used as control.
Nuclei were isolated as previously described [16] with some modiﬁ-
cations. Brieﬂy, nuclei were isolated from 2 106 cells and sus-
pended in 200 ll of nuclei lysis buffer (50 mM Tris–HCl, pH 7.5,
2.5 mMMgCl2, 2% SDS, 2 mM DTT, 5 mM NaF, 1 mM Na3VO4, prote-
ase inhibitor cocktail Set V (Calbiochem, Gibbstown, NJ) and benzon-
ase (ﬁnal concentration 2.5 U/ml)). The lysates were incubated for
30 min on ice and then centrifuged at 15000g for 20 min.
For SDS–PAGE, 40 ll of cytosolic or nuclear fraction, as well as
20 and 4 ll of nuclear fraction were loaded. Following primary
antibodies were used: CIDEA (Sigma–Aldrich, St. Louis, MO), GAP-
DH, Lamin A/C (both from Cell Signaling Technology, Danvers, MA)
and liver X receptor (LXR) (a gift from K.R. Steffensen, Karolinska
Institute, Stockholm, Sweden).2.3. Transactivation assay
COS-7 cell transfections were performed in serum free media for
2 h using the cationic lipid RPR120535B as described [17]. 3T3-L1
cells were transfected as described previously [8]. The plasmids
used for transfections were the reporter pGal5TKpGL3 [17] and
expression plasmids pGal4hLXRa, pGal4hLXRb, pGal4-hPPARcDEF,
pcDNA3.1 (Invitrogen, UK) and pcDNA3.1-hCIDEA [8]. pSV-bGal
was used as a control of transfection efﬁciency and cell viability.
The peroxisome proliferator-activated receptor c (PPARc) agonist
BRL49653 (5 lM), the LXR agonists T0901317 and GW3965 (both
at 1 lM) (Sigma–Aldrich) or vehicle alone were used to activate nu-
clear receptors after transfection. After 48 h cells were washed,
lysed and luciferase activity was measured using the Dual-Lucifer-
ase™ Reporter Assay System (Promega, Madison, WI). Only exper-
iments where the intra-experimental transfection efﬁciency and
cell viability were comparable were used for the study. Each exper-
imental group was tested in triplicate.2.4. Glutathione S-transferase (GST) pull-down assay
GST and GST-human nuclear receptor fusion proteins were
expressed in Escherichia coli BL21(DE3)-pLysS from pGEX-based
plasmids and puriﬁed as described [18]. CIDEA and RAP250
[19] were transcribed in vitro and translated with 35S-methio-
nine using TNT coupled reticulocyte lysate system (Promega).
GST bound fusion proteins were incubated for 2 h at 4 C with
2 ll of 35S-methionine-labeled protein in the presence of the
1 lM T0901317 or with vehicle alone in 200 ll of incubation
buffer (50 mM KPi, pH 7.4, 10% (v/v) glycerol, 100 mM NaCl,
1 mM MgCl2, 0.1% Tween) supplemented with 1.5 mg/ml bovine
serum albumin. Precipitated proteins were detected as described
[18].
2.5. Mammalian two-hybrid assay
We have used an assay based on the Matchmaker™Mammalian
Two-Hybrid system (Clontech, Mountain View, CA), which allows
testing protein–protein interactions in transfected mammalian
cells. The following plasmids were used for the transfections;
pUAS-tk-Luc (luciferase reporter), pM (coding for DNA binding
domain (DBD)), pVP16 (coding for activation domain), pM-CIDEA,
pM-TIF2, pVP16-LXRb, pCMVb-gal (to correct for transfection
efﬁciency) [19]. Transient transfections were performed in fat cells
differentiated in vitro for 10–12 days using Lipofectamine/Plus
reagent (Invitrogen). Cells were lysed 24 h after transfection and
assayed for luciferase and b-galactosidase activities. Each experi-
mental group was tested in triplicate.
2.6. Immunoprecipitation experiments
Mature human adipocytes were lysed in a buffer (50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 0.25% sodium deoxycholate and 1% NP-
40) supplemented with protease inhibitors. The pcDNA3.1-hCIDEA
andGal4-DBD constructswere translated in vitro using TNT coupled
reticulocyte lysate system (Promega) and 35S-methionine (GE
Healthcare, UK). The amount and integrity of the respective proteins
were assessed by running a small aliquot on SDS–PAGE and analyz-
ing the gel by autoradiography. After pre-clearingwith Protein-A se-
pharose (GE Healthcare), a similar amount of in vitro translated
proteins was incubated with 400 lg of protein lysate from human
mature adipocytes for 1 h. A mixture of monoclonal anti-LXRa/
NR1H3 and anti-LXRb/NR1H2 antibodies (R&D Systems, Minneapo-
lis,MN) ormouse serum IgGwere added and lysateswere incubated
overnight under rotation. Complexeswere precipitatedwith Protein
A-sepharose, washed and eluted by boiling in SDS-sample buffer.
Samples were then fractionated by SDS–PAGE followed by
autoradiography.
2.7. Statistical analysis
Statistical signiﬁcance was determined using non-parametric
Mann–Whitney test. P < 0.05 was considered signiﬁcant. Data are
mean ± standard deviation (S.D.).3. Results
3.1. The CIDEA sequence reveals motifs for nuclear receptor binding
In an effort to better understand the molecular mechanisms
through which CIDEA mediates its effects, an analysis of the
CIDEA protein sequence was performed to search for possible
protein–protein interaction domains. Two motifs were found that
could mediate interaction with nuclear receptors [20]. In the
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Fig. 1. CIDEA regulates activity of nuclear receptors. (A) Analysis of CIDEA protein sequence showing motives for nuclear receptor binding. (B) Transactivation assays in COS-7
cells (n = 4). (C) Transactivation assays in 3T3-L1 cells (n = 3). Values show the effect of agonist in each condition and are expressed as mean ± S.D., ⁄P < 0.05, ⁄⁄P < 0.01.
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(NR)-boxes while the N-terminal domain contains a CoRNR box,
which is present in co-repressors of nuclear receptors (Fig. 1A).
3.2. CIDEA regulates activity of LXRs
We hypothesized that CIDEA might regulate the activity of
nuclear receptors involved in adipocyte metabolism or differentia-
tion. Therefore, COS-7 cells were co-transfected with vector con-
taining cDNA for PPARc fused to Gal4-DBD, a Gal4-responsive
reporter and different amounts of hCIDEA-expressing vector. Cells
were treated with the PPARc agonist BRL49653. Our data showed
that presence of CIDEA had no effect on PPARc activity in this
system (Fig. 1B). We therefore chose to investigate CIDEAs effect
on the nuclear receptor LXR which has been implicated in the
regulation of fat cell metabolism [21–23]. Both LXRa and LXRb
markedly up-regulated luciferase activity following addition of
the LXR agonist T0901317 (Fig. 1B). Co-transfection of CIDEA
resulted in a concentration-dependent decrease of both LXRa and
LXRb activities. CIDEA over-expression had no effect on luciferase
activity in the absence of T0901317 (data not shown). These effects
were not restricted to COS-7 cells as similar effects were observed
in murine 3T3-L1 cells (Fig. 1C).3.3. CIDEA binds to LXR in vivo and in vitro
To investigate whether CIDEA can bind directly to LXR, a
pull-down assay was performed using an in vitro translated
35S-Cys-labeled human CIDEA and GST-tagged LXRb. In line with
the data from the transactivation assays, binding was observed
between CIDEA and LXR in this non-cellular assay (Fig. 2A). CIDEA
binding to LXR was not affected by LXR agonist T0901317. As a
positive control for the analysis, we used an in vitro translated
fragment containing the NR-box1 from RAP250 [19], which
showed a ligand-enhanced binding to LXRb (Fig. 2A). We also
determined whether CIDEA and LXR interact in adipocyte cell
extracts by co-immunoprecipitation. To this end, CIDEA was
in vitro-translated in the presence of 35S-methionine and incu-
bated with adipocyte lysates in presence of anti-LXR or control
IgG antibodies. The Gal4-DBD has no reported binding to LXR
and was therefore chosen as a negative control. Eluted proteins
were analyzed by SDS–PAGE and autoradiography. A clear band
corresponding to the size of CIDEA was detected in the samples
immunoprecipitated with the anti-LXR antibody but not with
unspeciﬁc IgG antibodies (Fig. 2B). There was no detectable band
in samples containing 35S-methionine labeled Gal4-DBD immuno-
precipitated with anti-LXR.
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Fig. 3. CIDEA is localized to nucleus and cytoplasm in adipocytes. Western blot
detection of CIDEA, GAPDH, Lamin A/C and LXR in cytosolic and nuclear extracts
from human adipocytes infected by CIDEA or GFP.
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in a living cell system, a mammalian two-hybrid assay [19] was set
up in differentiated human adipocytes. Co-transfection of the cells
with pM-CIDEA and pVP16-LXRb constructs resulted in a high li-
gand-dependent activity of the reporter gene (Fig. 2C), suggesting
an interaction between CIDEA and LXRb in human fat cells. In sim-
ilar experiments, there was no interaction between CIDEA and
PPARc (ﬁgure not shown). TIF2, a well established co-activator of
nuclear receptors served as a positive control [24].3.4. CIDEA is localized to both cytoplasm and the nucleus in adipocytes
Due to the low levels of endogenous CIDEA expressed in in vitro
differentiated human adipocytes, adenoviral infections were
performed with CIDEA- or GFP-expressing adenoviral particles fol-
lowed by extraction of nuclear and cytoplasmic lysates. Western
blot analysis demonstrated that virally over-expressed CIDEA and
endogenous LXR localized to both the cytoplasmic and the nuclear
fractions to a similar extent (Fig. 3). The nuclear protein Lamin A/C
and the cytoplasmic protein GAPDH were used as controls for pur-
ity of the nuclear and cytoplasmic fractions, respectively.
4. Discussion
Recent studies in humans and rodents suggest an important
role for CIDEA in regulating the metabolism of white adipocytes,
but the molecular mechanisms have remained largely unclear.
Here we provide evidence for an additional and hitherto unknown
mode of action for CIDEA in white fat cells.
Based on the analysis of the CIDEA protein sequence, we
hypothesized that it could interact with nuclear receptors. Given
the fact that CIDEA is predominantly expressed in adipocytes, we
focused on the possible interaction with nuclear receptors with
established roles in fat cell metabolism, namely PPARc and LXR
[25,26]. We demonstrate a physical interaction between CIDEA
and LXR using a set of distinct techniques including transactivation
and mammalian two-hybrid experiments. The latter suggest that
the CIDEA/LXR interaction is taking place in living cells and is
not solely an in vitro phenomenon.
The transactivation data obtained in COS-7 and murine 3T3-L1
cells indicate that CIDEA attenuates LXR activity. Thus, CIDEA may
act as a co-repressor of LXR, which is in agreement with the
ﬁnding that CIDEA binds to LXR in a ligand-independent manner.
Although CIDEA posses NR-binding motifs, mutations of NR- and
748 A. Kulyté et al. / FEBS Letters 585 (2011) 744–748CoRNR-boxes did not interfere with CIDEA binding to LXR in GST
pull-down assays or CIDEA co-repressor activity in transactivation
assays (data not shown). Therefore, it is likely that CIDEA interacts
with LXR via different domain than known NR-binding motifs. It is
at present unclear whether additional proteins bind or interact
with the CIDEA/LXR complex. If so, it is quite likely that such
regulatory proteins are differentially expressed in different cell
types. In addition, CIDEA is almost exclusively expressed in fat
cells [2–4], which could confer tissue-selective effects to LXRs.
CIDEA has been reported to induce ubiquitination and degradation
of AMP-activated protein kinase [9]. The amount of LXR is not
affected by CIDEA over-expression (Fig. 3), suggesting that CIDEA
does not affect stability of this nuclear receptor. At present, we
do not know whether CIDEA affects the recruitment of LXR to
DNA or its transcriptional activity.
Studies on the intracellular localization of CIDEA are hampered
by the absence of speciﬁc antibodies. Different molecular tags and
cell systems have therefore been used in order to elucidate the
intracellular compartmentalization of CIDEA [7,9–11]. Different CI-
DEA-fusion proteins localize to several compartments/organelles
in different cells. In our fractionation studies we over-expressed
untagged CIDEA. Although we admit that over expression might
cause some artiﬁcial effects, our data indicate that CIDEA is local-
ized to both the nucleus and the cytoplasm in human adipocytes.
A previous report demonstrated that nuclear over-expression of CI-
DEA induced apoptosis in MCF-7 cells [10]. In contrast, we did not
observe any increase in apoptosis or necrosis following CIDEA
over-expression in our cell systems (data not shown).
It would be important to determine, which metabolic pathways
are affected by CIDEA/LXR interaction. Both CIDEA and LXR regu-
late adipocyte lipolysis and substrate oxidation [3,4,8,21,27]. On
the other hand, LXR is a multifunctional transcription factor and
we cannot exclude that CIDEA would affect other metabolic path-
ways, regulated by LXR in adipocytes. Additional studies using
more sophisticated in vivo experimental systems are needed to
establish a physiological role for the CIDEA/LXR crosstalk.
In conclusion, both LXR and CIDEA regulate metabolism in
white adipocytes. We propose that CIDEA is a regulator of LXR
and possibly other nuclear receptors in fat cells. These interactions
could be of importance for adipose tissue metabolism and obesity,
an issue that will be addressed in future studies.
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